Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.57 |
| ▸ | EDNRA | P25101 | 1/20 | 0.56 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.54 |
| ▸ | IL1RN | P18510 | 3/20 | 0.52 |
| ▸ | MMP1 | P03956 | 3/20 | 0.52 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.52 |
| ▸ | ECE1 | P42892 | 4/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | CASP4 | P49662 | 1/20 | 0.51 |
| ▸ | CASP5 | P51878 | 1/20 | 0.51 |
| ▸ | CASP7 | P55210 | 1/20 | 0.51 |
| ▸ | CASP9 | P55211 | 1/20 | 0.51 |
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.51 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 5/20 | 0.50 |
| ▸ | MMP8 | P22894 | 4/20 | 0.50 |
| ▸ | MMP9 | P14780 | 3/20 | 0.50 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30680479 | 0.92 | ERAP2 (0.62) | ERAP2EDNRAMAGI3IL1RNMMP1 | |
| SCHEMBL22366982 | 0.90 | ERAP2 (0.67) | ERAP2IL1RNMMP1ERAP1ECE1 | |
| SCHEMBL1877672 | 0.87 | ERAP2 (0.64) | ERAP2EDNRAMAGI3IL1RNERAP1 | |
| SCHEMBL1877671 | 0.87 | ERAP2 (0.64) | ERAP2EDNRAMAGI3IL1RNERAP1 | |
| SCHEMBL30571040 | 0.86 | OPRM1 (0.57) | ERAP2EDNRAMAGI3MMP1ECE1 | |
| SCHEMBL30051725 | 0.86 | EDNRA (0.60) | ERAP2EDNRAMAGI3IL1RNMMP1 | |
| SCHEMBL30051322 | 0.86 | ECE1 (0.64) | ERAP2MMP1ECE1MMP2MMP8 | |
| SCHEMBL29519902 | 0.86 | MMP2 (0.61) | ERAP2IL1RNMMP1ERAP1ECE1 | |
| SCHEMBL31258887 | 0.85 | EDNRA (0.56) | ERAP2EDNRAMAGI3IL1RNERAP1 | |
| SCHEMBL30123123 | 0.85 | ERAP2 (0.76) | ERAP2IL1RNMMP1ERAP1ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132222-A1 | PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-12600792-B2 | Monoclonal antibodies and methods of use | ELANCO TIERGESUNDHEIT AG (CH) | 2026-04-14 | — | — | US | disclosed |
| US-12545746-B2 | Anti-BCMA car antibodies, conjugates, and methods of use | 2SEVENTY BIO, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20260035480-A1 | SICKLED BETA GLOBIN ANTIBODIES | BLUEBIRD BIO INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250368956-A1 | TGFBETA SIGNAL CONVERTOR | REGENERON PHARMA (US) | 2025-12-04 | — | — | US | disclosed |
| US-12479930-B2 | Proteins specific for BAFF and B7RP1 and uses thereof | AMGEN INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-12454580-B2 | FRB antibodies | REGENERON PHARMACEUTICALS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| EP-3689371-B1 | PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF | AMGEN INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12441792-B2 | Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereof | MERCK SHARP & DOHME LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-12435133-B2 | Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereof | MERCK SHARP & DOHME LLC (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4014996-A1 | ANTI-SIALYL TN CHIMERIC ANTIGEN RECEPTORS | Helixmith Co., Ltd (KR) | 2022-06-22 | — | — | EP | disclosed |
| US-11357849-B2 | Anti-nucleolin antibodies | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3456344-B1 | PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF | AMGEN INC (US) | 2022-05-04 | — | — | EP | disclosed |
| US-11319377-B2 | Monoclonal antibodies and methods of use | ELANCO TIERGESUNDHEIT AG (CH) | 2022-05-03 | — | — | US | disclosed |
| US-11279769-B2 | Anti-Sialyl Tn chimeric antigen receptors | HELIXMITH CO., LTD (KR) | 2022-03-22 | — | — | US | disclosed |
| CN-114206936-A | Compositions and methods for treating cancer | 2赛文缇生物公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2022046730-A2 | BCMA CHIMERIC ANTIGEN RECEPTORS | BLUEBIRD BIO, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20220034902-A1 | METHOD FOR IDENTIFYING HIGH AFFINITY MONOCLONAL ANTIBODY HEAVY AND LIGHT CHAIN PAIRS FROM HIGH THROUGHPUT SCREENS OF B-CELL AND HYBRIDOMA LIBRARIES | MERCK SHARP & DOHME CORP. (US) | 2022-02-03 | — | — | US | disclosed |
| US-11236169-B2 | Anti-DEspR monoclonal antibody targeted therapy and imaging for cancer and stroke | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-02-01 | — | — | US | disclosed |
| US-20220025042-A1 | ANTIBODIES SPECIFIC FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132222-A1 | PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF | SSB, IGSF11, CD22 | ERAP2 2159/4885EDNRA 1741/4885MAGI3 4591/4885 |
| US-12600792-B2 | Monoclonal antibodies and methods of use | IGSF11, IGLV6-57, CDY1; CDY1B | ERAP2 4477/4885EDNRA 4428/4885MAGI3 4108/4885 |
| US-12545746-B2 | Anti-BCMA car antibodies, conjugates, and methods of use | CD47, RBM25, CD22 | ERAP2 1524/4885EDNRA 1291/4885MAGI3 4236/4885 |
| US-20260035480-A1 | SICKLED BETA GLOBIN ANTIBODIES | HBB, HBZ, HBG2 | ERAP2 1519/4885EDNRA 2982/4885MAGI3 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.